# A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants

> **NCT05471817** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 20 (actual)

## Conditions studied

- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
- Hot Flashes
- Healthy Volunteers

## Interventions

- **DRUG:** Elinzanetant (BAY3427080)
- **DRUG:** Dabigatran etexilate

## Key facts

- **NCT ID:** NCT05471817
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-05
- **Primary completion:** 2022-09-20
- **Final completion:** 2022-11-14
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05471817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05471817, "A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05471817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*